- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00909532
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation (STRIVE)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects With Cystic Fibrosis and the G551D Mutation
연구 개요
상세 설명
This was a phase 3 study in subjects with cystic fibrosis (CF) age 12 years and older who have a G551D-CFTR mutation and percent predicted forced expiratory volumn in 1 second (FEV1) between 40% and 90%.
Based on in vitro studies and pharmacologic, pharmacokinetic (PK), and safety profiles, ivacaftor was selected for clinical development as a possible treatment for patients with CF. Patients with the G551D mutation were the targeted population for this study because ivacaftor is a potentiator of the gating function of the CFTR protein, and the most prevalent mutation with a gating defect in CF is the G551D mutation.
This study was designed to further evaluate the efficacy of ivacaftor in subjects with CF who have a G551D-CFTR gene mutation and to evaluate safety in this population over a longer period than previously studied.
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Erlangen, 독일, 91054
- Kinder- und Jugendklinik Universitätsklinikum Erlangen
-
Jena, 독일, 07740
- Mukoviszidose-Zentrum am Klinikum der Friedrich-Schiller-Universität Jena, Klinik für Kinder- und Jugendmedizin
-
Munich, 독일, 80337
- Klinikum der LMU München, Dr. von Haunersches Kinderspital (CHA)
-
Wurzburg, 독일, 97080
- Universitäts-Kinderklinik Würzburg
-
-
-
-
Alabama
-
Birmingham, Alabama, 미국, 35233-1711
- University of Alabama
-
-
California
-
Oakland, California, 미국, 94611
- Kaiser Permanente Medical Care Program
-
Palo Alto, California, 미국, 94304
- Cystic Fibrosis Research Office, Stanford University
-
San Diego, California, 미국, 92123-5070
- Rady Children's Hospital
-
-
Colorado
-
Denver, Colorado, 미국, 80206
- National Jewish Medical and Research Center
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- Emory Cystic Fibrosis Center
-
-
Idaho
-
Boise, Idaho, 미국, 83712
- St. Luke's CF Clinic
-
-
Illinois
-
Chicago, Illinois, 미국, 60614
- Children's Memorial Hospital
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- Indiana University
-
-
Iowa
-
Iowa City, Iowa, 미국, 52242
- University of Iowa
-
-
Maryland
-
Baltimore, Maryland, 미국, 21205
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, 미국, 02115
- Children's Hospital Boston
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- University of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55455
- Pulmonary, Allergy & Critical Care Medicine, University of Minnesota
-
-
Missouri
-
Kansas City, Missouri, 미국, 64108
- The Children's Mercy Hospital
-
St. Louis, Missouri, 미국, 63110
- Washington University
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68198-5300
- Adult Pulmonary/ CF, University of Nebraska Medical Center
-
-
New Jersey
-
Long Branch, New Jersey, 미국, 07740
- Monmouth Medical Center
-
-
New York
-
Buffalo, New York, 미국, 14222
- Women and Children's Hospital of Buffalo
-
New Hyde Park, New York, 미국, 11042
- Long Island Jewish Medical Center
-
Syracuse, New York, 미국, 13210
- SUNY Upstate Medical University
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27599
- University of North Carolina at Chapel Hill
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, 미국, 44106
- Pediatric & Pulmonary Division, Rainbow Babies/Case Western
-
Columbus, Ohio, 미국, 43205
- Nationwide Children's Hospital
-
Toledo, Ohio, 미국, 43606
- Toledo Children's Hospital
-
-
Oregon
-
Portland, Oregon, 미국, 97239-3098
- Oregon Health & Sciences University
-
-
Pennsylvania
-
Hershey, Pennsylvania, 미국, 17033
- Hershey Medical Center
-
Philadelphia, Pennsylvania, 미국, 19104
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, 미국, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Tennessee
-
Knoxville, Tennessee, 미국, 37916
- East Tennessee Children's Hospital
-
Nashville, Tennessee, 미국, 37232-5735
- Vanderbilt University Medical Center
-
-
Utah
-
Salt Lake City, Utah, 미국, 84132
- University of Utah
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22908
- University of Virginia
-
-
Washington
-
Seattle, Washington, 미국, 98105
- Seattle Children's Hospital
-
Seattle, Washington, 미국, 98195-6522
- Division of Pulmonary and CCM, University of Washington
-
-
West Virginia
-
Morgantown, West Virginia, 미국, 26506
- West Virginia University
-
-
Wisconsin
-
Milwaukee, Wisconsin, 미국, 53226
- Medical College of Wisconsin
-
-
-
-
-
Cork, 아일랜드
- Cork University Hospital
-
Dublin, 아일랜드, 9
- Beaumont Hospital
-
Dublin, 아일랜드, 4
- St. Vincent's University Hospital
-
Dublin, 아일랜드, 12
- Our Lady's Children's Hospital
-
Dublin, 아일랜드, 24
- The National Children's Hospital
-
-
-
-
-
London, 영국, SW3 6LR
- Imperial College London
-
-
Northern Ireland
-
Belfast, Northern Ireland, 영국, BT9 7AB
- Belfast City Hospital
-
-
-
-
-
Prague, 체코 공화국, 15006
- FN Motol
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, 캐나다, B3H 3A7
- Queen Elizabeth Ii Health Sciences Centre
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5B 1W8
- St. Michael's Hospital
-
Toronto, Ontario, 캐나다, M5G 1X8
- CF Center, Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, 캐나다, H3H 1P3
- Montreal Children's Hospital - MUHC
-
-
-
-
-
Paris, 프랑스, 75014
- Hopital Cochin
-
Paris, 프랑스, 75015
- Hopital Necker
-
Roscoff, 프랑스, 29684
- Centre de Perharidy
-
-
-
-
New South Wales
-
Westmead, New South Wales, 호주, 2145
- The Children's Hospital Westmead
-
-
Queensland
-
Chermside, Queensland, 호주, 4032
- The Prince Charles Hospital
-
Herston, Queensland, 호주, 4026
- Royal Children's Hospital Brisbane
-
South Brisbane, Queensland, 호주, 4101
- Mater Adult Hospital
-
-
Victoria
-
Parkville, Victoria, 호주, 3052
- Royal Children's Hospital Melbourne
-
-
Western Australia
-
Nedlands, Western Australia, 호주, 6009
- Lung Institute of Western Australia
-
Subiaco, Western Australia, 호주, 6008
- Princess Margaret Hospital for Children
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Confirmed diagnosis of cystic fibrosis (CF) and G551D mutation in at least 1 allele
- Forced expiratory volume in 1 second (FEV1) of 40% to 90% (inclusive) of predicted normal for age, gender, and height at Screening.
- No clinically significant abnormalities that would have interfered with the study assessments, as judged by the investigator
- Willing to use highly effective birth control methods during the study
Exclusion Criteria:
- History of any illness or condition that might confound the results of the study or pose an additional risk in administering study drug to the subject
- Acute respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks of Day 1 of the study
- History of alcohol, medication or illicit drug abuse within one year prior to Day 1
- Abnormal liver function ≥ 3x the upper limit of normal
- Abnormal renal function at Screening
- History of solid organ or hematological transplantation
- Pregnant, planning a pregnancy, breast-feeding, or unwilling to follow contraception requirements
- Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within 30 days prior to Screening
- Use of inhaled hypertonic saline treatment
- Concomitant use of any inhibitors or inducers of cytochrome P450 3A4 (CYP 3A4)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
위약 비교기: 위약
최대 48주 동안 12시간마다(q12h) 위약을 투여받은 피험자.
|
최대 48주 동안 q12h 구두로 정제 제공
|
실험적: 150 mg Ivacaftor q12h
최대 48주 동안 ivacaftor q12h 150mg을 투여받은 피험자.
|
150-mg tablets given orally q12h for up to 48 weeks
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24
기간: baseline through 24 weeks
|
Spirometry (as measured by FEV1) is a standardized assessment to evaluate lung function that is the most widely used endpoint in cystic fibrosis studies.
|
baseline through 24 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
기준선에서 24주 및 48주까지 땀 염화물 농도의 절대 변화
기간: 기준선에서 24주 및 48주까지
|
땀 염화물(정량적 필로카르핀 이온토포레시스) 검사는 낭포성 섬유증(CF)의 표준 진단 도구로, 낭포성 섬유증 막횡단 전도도 조절인자(CFTR) 활동의 지표 역할을 합니다.
|
기준선에서 24주 및 48주까지
|
24주차 및 48주차에 기준선에서 체중의 절대 변화
기간: 기준선에서 24주 및 48주
|
폐 질환 및 지방 흡수 장애로 인한 에너지 소비 증가로 인해 낭포성 섬유증(CF) 환자에서 영양실조가 흔하기 때문에 체중은 영양 상태의 중요한 임상 척도입니다.
|
기준선에서 24주 및 48주
|
Absolute Mean Change From Baseline in Percent Predicted FEV1 Through Week 48
기간: baseline through 48 weeks
|
Spirometry (as measured by FEV1) is a standardized assessment to evaluate lung function that is the most widely used endpoint in cystic fibrosis studies.
|
baseline through 48 weeks
|
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Score Through Week 24 and Week 48 (Respiratory Domain Score, Pooled)
기간: baseline through 24 weeks and 48 weeks
|
The CFQ-R is a health-related quality of life measure for subjects with cystic fibrosis.
Each domain is scored from 0 (worst) to 100 (best).
A difference of at least 4 points in the respiratory domain score of the CFQ-R is considered a minimal clinically important difference (MCID).
|
baseline through 24 weeks and 48 weeks
|
Time-to-first Pulmonary Exacerbation Through Week 24 and Week 48
기간: baseline through 24 weeks and 48 weeks
|
Pulmonary exacerbation was defined as a change in antibiotic therapy (intravenous, inhaled, or oral) for any 4 or more of signs/symptoms such as change in sputum; new or increased hemoptysis; increased cough or dyspnea; malaise, fatigue, or lethargy; temperature above 38 degrees C; anorexia or weight loss; sinus pain/tenderness and discharge; change in physical examination of the chest; decreased pulmonary function by 10%; and radiographic changes indicative of pulmonary infection.
|
baseline through 24 weeks and 48 weeks
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Bonnie W. Ramsey, MD, Children's Hospital and Regional Medical Center, Seattle, Washington, USA
- 수석 연구원: Stuart Elborn, MD, Respiratory Medicine Group, Queen's University of Belfast, Belfast, Northern Ireland, UK
간행물 및 유용한 링크
일반 간행물
- Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordonez C, Elborn JS; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185.
- Flume PA, Wainwright CE, Elizabeth Tullis D, Rodriguez S, Niknian M, Higgins M, Davies JC, Wagener JS. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. J Cyst Fibros. 2018 Jan;17(1):83-88. doi: 10.1016/j.jcf.2017.06.002. Epub 2017 Jun 24.
- Solem CT, Vera-Llonch M, Liu S, Botteman M, Castiglione B. Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis. Health Qual Life Outcomes. 2016 Apr 21;14:63. doi: 10.1186/s12955-016-0465-z.
- Quittner A, Suthoff E, Rendas-Baum R, Bayliss MS, Sermet-Gaudelus I, Castiglione B, Vera-Llonch M. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial. Health Qual Life Outcomes. 2015 Jul 2;13:93. doi: 10.1186/s12955-015-0293-6.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- VX08-770-102
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
위약에 대한 임상 시험
-
AJU Pharm Co., Ltd.OM Pharma SA모병
-
University Hospital, Strasbourg, France모집하지 않고 적극적으로